Healthy kidneys make erythropoietin, the hormone that tells bone marrow to produce red blood cells. As kidney function declines, that signal fades, and anemia follows.
Which is true, and is also the reason the diagnosis so often stops there.
"It's from your kidneys" is where the workup ends
A patient has an abnormal eGFR and an anemia. The eGFR explains the anemia. Nobody looks further.
But an abnormal kidney function does not mean the anemia came from the kidney. It means one plausible cause is present, and a plausible cause is exactly what stops people from finding the real one.
Iron deficiency is nearly universal in chronic kidney disease and is frequently the entire explanation. Correct it and the anemia resolves without any erythropoietin at all. It is missed because nobody checks a transferrin saturation — and because a normal ferritin, in an inflamed patient, looks reassuring and is not.
Light chain disease — multiple myeloma and related plasma cell disorders — causes anemia and kidney dysfunction together. Both get blamed on the kidney. The myeloma is found years late, if at all.
Gastrointestinal blood loss. B12 and folate deficiency. Hemolysis. Thyroid disease.
An anemia disproportionate to the eGFR, or one that does not respond to iron and erythropoietin, is not kidney anemia. It is something else wearing kidney anemia's clothes.
Board-certified nephrology at Remix Medical in Houston. Call (713) 597-5131 or book online.
Why it matters more than the number suggests
Patients are often told their anemia is "mild" and left there. But the fatigue is real, and it is frequently the symptom that most degrades daily life in chronic kidney disease — more than the creatinine, which they cannot feel at all.
Anemia also drives left ventricular hypertrophy, worsens heart failure, and is independently associated with cardiovascular death and faster progression to kidney failure.
Erythropoietin is not the whole story
The reflex is to reach for an erythropoiesis-stimulating agent. That is usually the wrong first move.
Iron deficiency comes first, and it is nearly universal. In chronic kidney disease, inflammation raises hepcidin, which locks iron inside storage cells where the marrow cannot reach it. So you can have adequate ferritin and still be functionally iron deficient.
This is why a normal ferritin does not exclude iron deficiency in kidney disease. Transferrin saturation matters as much, and the thresholds differ from the ones used in the general population.
Oral iron is poorly absorbed in chronic kidney disease and often fails. Intravenous iron works, and for many patients it corrects the anemia without any erythropoietin at all.
When we do use an ESA
Epoetin or darbepoetin, and the target is deliberately conservative. Hemoglobin between 10 and 11.5 g/dL.
Not higher. Trials targeting normal hemoglobin found more strokes, more clotting, and more deaths. Correcting the number all the way turned out to harm people. That finding reshaped the field, and the modest target is a direct consequence of it.
This is a case where treating to a normal laboratory value is worse than treating to an abnormal one.
A newer option: HIF-PHI agents
Hypoxia-inducible factor prolyl hydroxylase inhibitors are oral drugs that raise hemoglobin by a different route. Rather than supplying erythropoietin from outside, they mimic the body's own response to low oxygen — increasing endogenous erythropoietin production and improving how iron is mobilized from storage.
An oral alternative to an injection is not a small thing for someone facing years of therapy.
They are an option, not a replacement. The same hemoglobin ceiling applies. Cardiovascular and thrombotic safety differs across the class, and there are drug interactions that matter. Whether one suits you depends on your iron status, your cardiovascular history, and whether you are on dialysis.
Most patients have never been told this class exists. It is worth asking about.
What we do
Establish the cause before treating the number. Hemoglobin, ferritin, and transferrin saturation together — never ferritin alone, which inflammation renders unreliable.
Screen for gastrointestinal blood loss. Rule out B12, folate, and thyroid causes. Check a serum protein electrophoresis and free light chains when the picture does not fit, because myeloma presenting as anemia plus kidney dysfunction is a diagnosis that is routinely made two years late.
Replete iron intravenously before any erythropoiesis-stimulating agent, because for many patients that is the whole treatment.
Then an ESA or a HIF-PHI only if needed, to a target of 10 to 11.5, monitored closely.
An anemia with an abnormal eGFR is not automatically kidney anemia. If nobody checked your iron saturation, or looked past the kidney, the question is still open.
Call (713) 597-5131 or book online.